Clonic hemifacial spasm, left
Methodology & AI Transparency ⓘ
Clonic hemifacial spasm, left Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Clonic hemifacial spasm, left (ICD-10-CM G51.32), Neurology, Stroke & Movement Disorders protocols prioritize CSF/autoimmune antibody panels in Clonic hemifacial spasm, left (G51.32: when indicated) paired with baseline and interval Serum Vitamin B12 in Clonic hemifacial spasm, left (G51.32: & Methylmalonic Acid) assessment.
- 2 Real-world patient consensus: Mapped to Neurology, Stroke & Movement Disorders under ICD-10-CM G51.32 for Clonic hemifacial spasm, left clinical workups.
- 3 Typical cash cost range: Differential triage of Clonic hemifacial spasm, left (G51.32) utilizes CSF/autoimmune antibody panels in Clonic hemifacial spasm, left (G51.32: when indicated).
- 4 Top reported side effects / signs: Key Brain & Neurology biomarkers for Clonic hemifacial spasm, left (G51.32): Serum Vitamin B12 in Clonic hemifacial spasm, left (G51.32: & Methylmalonic Acid) & Carotid Duplex / in Clonic hemifacial spasm, left (G51.32: Cerebral Perfusion) (No hemodynamically significant stenosis (G51.32)).
Ask our AI Specialists anything about Clonic hemifacial spasm, left
What Is Clonic hemifacial spasm, left?
For patients presenting with Clonic hemifacial spasm, left (ICD-10-CM G51.32), Neurology, Stroke & Movement Disorders protocols prioritize CSF/autoimmune antibody panels in Clonic hemifacial spasm, left (G51.32: when indicated) paired with baseline and interval Serum Vitamin B12 in Clonic hemifacial spasm, left (G51.32: & Methylmalonic Acid) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Clonic hemifacial spasm, left (G51.32) alters brain & neurology homeostasis through or basal ganglia in Clonic hemifacial spasm, left (G51.32: dopaminergic circuit degeneration); clinical remission targets Carotid Duplex / in Clonic hemifacial spasm, left (G51.32: Cerebral Perfusion) within No hemodynamically significant stenosis (G51.32).
Common Symptoms & Clinical Signs
- • Presentation of Clonic hemifacial spasm, left (G51.32): numbness, paresthesia, or in Clonic hemifacial spasm, left (G51.32: visual field/speech changes)
- • Secondary Clonic hemifacial spasm, left clinical sign: muscle stiffness, spasticity, in Clonic hemifacial spasm, left (G51.32: or fatigable neuromuscular)
- • Symptom flares in Clonic hemifacial spasm, left correlating with Serum Vitamin B12 in Clonic hemifacial spasm, left (G51.32: & Methylmalonic Acid) deviation outside B12 > 500 pg/mL; MMA < 240 nmol/L (G51.32)
- • Functional brain & neurology impact requiring CSF/autoimmune antibody panels in Clonic hemifacial spasm, left (G51.32: when indicated) evaluation (G51.32)
Clonic hemifacial spasm, left Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G51.32 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Clonic hemifacial spasm, left (G51.32: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G51.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Clonic hemifacial spasm, left (G51.32: Cerebral Perfusion) | No hemodynamically significant stenosis (G51.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Clonic hemifacial spasm, left (G51.32: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G51.32) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Clonic hemifacial spasm, left
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Phenytoin Dilantin-125, Dilantin Infatabs • RxCUI 1313112 | Anti-epileptic Agent | 77% | $0.1812 | $ 7.10 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Clonic hemifacial spasm, left)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Multiple sclerosis clinical decision support system based on projection to The pioneer use of PORs for each individual patient enables personalized analytics sustaining the dialog between neurologists, patients and caregivers with quantified evidence. Annals of clinical and translational neurology • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36412095 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, safety, and tolerability of adjunctive perampanel in patients from Adjunctive perampanel (up to 12 mg/day) may be a suitable treatment for Chinese patients with FS, with/without FBTCS, or GTCS, with similar real-world benefits and safety/tolerability compared to non-Chinese patients. CNS neuroscience & therapeutics • 2021-03-15 • Phase III Randomized Trial | N = 79 | 88/100 | PMID 33340263 ↗ |
| Can This Approach Help? Inside the Latest Research on Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter Findings reported here add new insights into the complex mechanisms of pseudo-atrophy and its relation to the compartmentalized inflammation occurring in the GM of MS patients. Annals of clinical and translational neurology • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33534940 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of adjunctive perampanel in patients with focal seizures or 128 patients (placebo, n = 39; perampanel, n = 89) were included in the gold-standard blind Safety Analysis Set and 126 (FS, n = 113 [placebo, n = 32; perampanel, n = 81]; FBTCS, n = 35 [placebo, n = 14; perampanel, n = 21];... Epilepsia open • 2021-03-15 • Phase III Randomized Trial | N = 39 | 88/100 | PMID 33681652 ↗ |
Clonic hemifacial spasm, left Patient Community & “People Like Me” Threads
Filter Clonic hemifacial spasm, left community threads and patient logs by age, biological sex, dosage, and treatment duration.